We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Investigating the "Mutational Burden" of Human Induced Pluripotent Stem Cells

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

By identifying and characterizing specific types of mutations in individual cell lines, using a combination of whole genome sequencing and multi-omic approaches, researchers hope to improve stem cell therapeutic uses and potential.

The therapeutic potential of human induced pluripotent stem cells (iPSCs), which can differentiate into almost any type of cell in the human body, is well-recognized and broadly pursued, but their mutational burden (the total number of mutations per coding area of a tumor genome) has not been fully characterized.

IPSCs are reprogrammed from somatic tissues, including skin cells that may accumulate many somatic mutations (mutations that are not inherited) due to exposure to sunlight and ultraviolet radiation. While previous studies have partially characterized somatic mutations present in iPSCs, a complete understanding of their mutational burden is lacking, despite more than 1,000 iPSC lines having been developed worldwide.

In a new study, published in this week’s issue of Cell Reports, researchers at the University of California San Diego School of Medicine scrutinized the whole genome sequences of 18 iPSC lines derived from skin cells that they had reprogrammed to identify and characterize somatic mutations.

“Induced pluripotent stem cells represent a huge opportunity for science and medicine, but to truly and effectively use them we need to more completely understand their mutational burden,” said senior author Kelly A. Frazer, PhD, director of the UC San Diego Institute for Genomic Medicine and founding chief of the Division of Genome Information Sciences in the UC San Diego School of Medicine.

“If we can detect somatic mutations for each iPSC line on an individual basis, we can use that information to prioritize iPSC lines for models of specific human diseases and/or transplantation therapies.”

In their research, Frazer and colleagues used whole-genome sequencing, transcriptome and epigenome data to identify and characterize mutations in 18 iPSC lines included in the iPSCORE Resource and publicly available at WiCell, a non-profit that provides stem cell lines for research and testing.

The researchers classified extensively two previously identified classes of somatic mutations in iPSCs, which were clonal mutations derived from the parental cell and copy-number alterations (duplications or deletions of larger portions of a chromosome).

In addition, they discovered and characterized two new classes of mutations, one of which was caused by ultraviolet radiation damage in the parental cell. The other subclonal mutations were not present in the parental cell and occurred during iPSC reprogramming.

The researchers found that while the vast majority of mutations are in epigenetic regions associated with closed chromatin and do not alter gene expression, subclonal mutations that occurred during iPSC reprogramming showed an increased association with active chromatin and altered gene expression.

This article has been republished from materials provided by UC San Diego Health. Note: material may have been edited for length and content. For further information, please contact the cited source.

Dantonio, M., Benaglio, P., Jakubosky, D. A., Greenwald, W. W., Matsui, H., Donovan, M. K., . . . Frazer, K. A. (2018). Insights into the mutational burden of human induced pluripotent stem cells using an integrative omics approach. Cell Reports doi:10.1101/334870